18349-09-2

Basic information

• Product Name: 2-BROMO-6-FLUORO-4-METHYLANILINE
• Synonyms: 2-BROMO-6-FLUORO-4-METHYLANILINE;2-Bromo-6-fluoro-4-methyl-phenylamine;Benzenamine, 2-bromo-6-fluoro-4-methyl-
• CAS NO: 18349-09-2
• Molecular Formula: C₇H₇BrFN
• Molecular Weight: 204.04
• Product Categories: Anilines, Amides & Amines;Bromine Compounds;Fluorine Compounds
• Mol File: 18349-09-2.mol

Chemical Properties

• Boiling Point: 231.6°C at 760 mmHg
• Flash Point: 93.9°C
• Appearance: /
• Density: 1.589g/cm³
• Vapor Pressure: 0.0617mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 2-BROMO-6-FLUORO-4-METHYLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-6-FLUORO-4-METHYLANILINE(18349-09-2)
• EPA Substance Registry System: 2-BROMO-6-FLUORO-4-METHYLANILINE(18349-09-2)

Safety Data

• Hazardous Substances Data: 18349-09-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-6-fluoro-4-methylaniline is used as an intermediate in the synthesis of pharmaceuticals for its potential anti-inflammatory and antibacterial properties. It plays a crucial role in the development of medicinal compounds that can address various health conditions.
Used in Agrochemical Industry:
2-BROMO-6-FLUORO-4-METHYLANILINE is also utilized in the production of agrochemicals, contributing to the development of effective solutions for agricultural applications, such as pesticides and herbicides, to protect crops and enhance yield.
Used in Dye and Pigment Industry:
2-Bromo-6-fluoro-4-methylaniline is employed in the manufacturing of dyes and pigments due to its chemical properties. It serves as a valuable intermediate in creating a wide range of colorants used in various industries, including textiles, plastics, and printing inks.
Used in Specialty Chemicals Production:
Furthermore, 2-BROMO-6-FLUORO-4-METHYLANILINE finds application in the production of specialty chemicals, which are used in specific industries for their unique properties. These specialty chemicals can be found in applications such as coatings, adhesives, and sealants, where their distinct characteristics are highly beneficial.

InChI:InChI=1/C7H7BrFN/c1-4-2-5(8)7(10)6(9)3-4/h2-3H,10H2,1H3

Upstream product

• 452-80-2 2-fluoro-4-methylaniline 

Downstream Products

• 1023971-89-2 2-bromo-6-fluoro-4-methylbenzonitrile 
• 932373-59-6 1,1-dimethylethyl4-({[(2-bromo-6-fluoro-4-methylphenyl)-amino]carbonyl}amino)-1-piperidinecarboxylate 
• 1403878-69-2 ethyl N-({4-[(1R,2S)-1-(4-chlorophenyl)-1-{7-fluoro-5-methyl-1-[(4-nitrophenyl)sulfonyl]-1H-indol-3-yl}pentan-2-yl]phenyl}carbonyl)-β-alaninate 
• 1234779-91-9 C₃₇H₃₅ClFN₃O₇S 
• 442910-91-0 7-fluoro-5-methyl-1H-indole 
• 1234779-88-4 7-fluoro-5-methyl-1-[(4-nitrophenyl)sulfonyl]-1H-indole 
• 1403878-72-7 2-ethynyl-6-fluoro-4-methylaniline 
• 1234779-89-5 4-[(1R,2S)-1-(4-chlorophenyl)-1-{7-fluoro-5-methyl-1-[(4-nitrophenyl)sulfonyl]-1H-indol-3-yl}pentan-2-yl]benzoic acid 
• 1403878-71-6 C₁₂H₁₄FNO 
• 1352877-28-1 methyl 2-bromo-5-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-3-fluorobenzoate 
• 1378427-79-2 5-cyclopropyl-6-(N-((7-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)methyl)methylsulfonamido)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide 
• 1378431-05-0 methyl 2-bromo-5-(bromomethyl)-3-fluorobenzoate 
• 1440415-14-4 C₂₉H₂₇BF₂N₂O₈S 
• 1378431-03-8 methyl 2-bromo-3-fluoro-5-methylbenzoate 

Relevant articles and documents

POLYCYCLIC COMPOUND AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND OR THE COMPOSITION

Specific polycyclic compounds, a material for an organic electroluminescence device comprising said specific polycyclic compound, an organic electroluminescence device comprising said specific polycyclic compound, an electronic equipment comprising said organic electroluminescence device, a process for preparing said polycyclic compounds, and the use of said polycyclic compounds in an organic electroluminescence. (Formula I) (I)

Direct Formic Acid Mediated Z-Selective Reductive Coupling of Dienes and Aldehydes

Methods for the addition of unsaturated nucleophiles to carbonyls to generate Z-olefin products remain rare and often require either alkyl borane or zinc reductants, limiting their utility. Demonstrated here is that formic acid mediates the Rh-catalyzed,

NOVEL ANTIBIOTICS AND METHODS OF USING SAME

The present invention includes novel 3,6-diazabicyclo[3.1.1]heptane antibiotic compounds and any salts or solvates thereof. The present invention further includes methods of preparing such compounds, and methods of treating bacterial infection in a subjec

CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF

Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA)

The C-5 substituted 2,4-diaminoquinazoline RG3039 (compound 1), a member of a chemical series that was identified and optimized using an SMN2 promoter screen, prolongs survival and improves motor function in a mouse model of spinal muscular atrophy (SMA).

A transition metal complex compound, and the compound of the catalyst and a catalyst for large amt. pentavelent carried out in the presence of an olefin multimer manufacturing method

PROBLEM TO BE SOLVED: To provide a transition metal complex compound, to provide an olefin polymerizing catalyst, containing the compound, and having excellent activity, and to provide a method for producing the olefin polymer which is carried out in the presence of the catalyst.SOLUTION: There is provided the transition metal complex compound of compound 3, e.g. of chemical formula; and the olefin polymerizing catalyst including following components (A) and (B): (A) the transition metal compound; and (B) at least one compound selected from the group consisting of (B-1) an organometallic compound, (B-2) an organoaluminumoxy compound, and (B-3) a compound reactive with the transition metal compound (A), and forming an ion pair.

Asymmetric synthesis of a glucagon receptor antagonist via friedel-crafts alkylation of indole with chiral α-phenyl benzyl cation

Development of a practical asymmetric synthesis of a glucagon receptor antagonist drug candidate for the treatment of type 2 diabetes is described. The antagonist consists of a 1,1,2,2-tetrasubstituted ethane core substituted with a propyl and three aryl groups including a fluoro-indole. The key steps to construct the ethane core and the two stereogenic centers involved a ketone arylation, an asymmetric hydrogenation via dynamic kinetic resolution, and an anti-selective Friedel-Crafts alkylation of a fluoro-indole with a chiral α-phenyl benzyl cation. We also developed two new efficient syntheses of the fluoro-indole, including an unusual Larock-type indole synthesis and a Sugasawa-heteroannulation route. The described convergent synthesis was used to prepare drug substance in 52% overall yield and 99% ee on multikilogram scales.

CRYSTALLINE POLYMORPHIC FORMS OF AN ANTIDIABETIC COMPOUND

The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.

Synthesis of RHPS4 via an anionic ring closing cascade

A new and convergent synthesis of the potent telomerase inhibitor RHPS4 is presented. The key step is the construction of the pentacyclic framework via an anionic ring closing cascade in which two new rings are formed.

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds which have activity at M1 receptor and their uses in medicine Compounds of formula (I) and salts and solvates are provided: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl